Regend is a global industry leader in the field of regenerative medicine for human organs.Its core product, REGEND001 cell preparation, has been accepted by the state food and drug administration and is the world's first autologous stem cell product for respiratory diseases.The company is also the first enterprise in China that has been registered by the national health and fitness commission and the food and drug administration to permit the development of stem cell clinical research (registration number: cmr-20161214-1002).At the same time, it is also the first enterprise to undertake the project of "stem cell and transformation research" under the key research and development program of the ministry of science and technology.At present, the company has passed ISO9001:2008 quality management system certification, stem cell preparation through China metrology certification (CMA), China conformity assessment committee (CNAS) and IAF international mutual recognition.All clinical programs are conducted in strict compliance with national health and drug administration regulations and are registered with the national institutes of health's ClinicalTrial global database.

    Founded in 2015 by a number of doctors returning from overseas study, Regend has r&d and business offices in suzhou, nanchang (Xlotus medical), Shanghai, hangzhou, guangzhou and Tokyo, Japan.The company builds an industrial chain around the basic research and development, pre-clinical development, clinical trials and commercialization of regenerative medicine related products, and promotes the transformation of scientific and technological achievements by applying the most cutting-edge life science achievements in the fields of clinical cell therapy and health diagnosis.Jiangxi Xlotus medical technology as the core platform of Regend  group, will set up a 10,000-square-meter r&d platform for cell therapy products (stem cells) in line with international standards, GMP production line, testing platform and tissue stem cell bank with reference to fda-cgmp.In addition to the company's product chain, the company will also provide one-stop (CDMO) high standard service for domestic and foreign cell therapy products enterprises.

    Regend aims to promote the third medical revolution based on cell therapy technology, leading the pursuit of the great dream of "regenerative medicine to restart life".We persist in integrating the spirit of innovation into the company's genes, take patient needs and scientific drive as the driving force, give play to creative scientific ideas and follow rigorous scientific evaluation.Regend solemn commitment: will always put the lives and health of the majority of consumers and patients in the first place.The knowledge and conscience of all Regend scientists, managers, shareholders, employees and partner medical workers are dedicated to the promotion and protection of patient health.We should never neglect the health and rights of any consumer or patient solely for the sake of scientific knowledge or commercial gain.